Berchuck A - Search Results

1

Racial Differences in the Tumor Immune Landscape and Survival of Women with High-Grade Serous Ovarian Carcinoma.

Peres LC, Colin-Leitzinger C, Sinha S, Marks JR, Conejo-Garcia JR, Alberg AJ, Bandera EV, Berchuck A, Bondy ML, Christensen BC, Cote ML, Doherty JA, Moorman PG, Peters ES, Moran Segura C, Nguyen JV, Schwartz AG, Terry PD, Wilson CM, Fridley BL, Schildkraut JM. Peres LC, et al. Among authors: berchuck a. Cancer Epidemiol Biomarkers Prev. 2022 May 4;31(5):1006-1016. doi: 10.1158/1055-9965.EPI-21-1334. Cancer Epidemiol Biomarkers Prev. 2022. PMID: 35244678 Free PMC article.

2

Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation.

Jacobs IJ, Kohler MF, Wiseman RW, Marks JR, Whitaker R, Kerns BA, Humphrey P, Berchuck A, Ponder BA, Bast RC Jr. Jacobs IJ, et al. Among authors: berchuck a. J Natl Cancer Inst. 1992 Dec 2;84(23):1793-8. doi: 10.1093/jnci/84.23.1793. J Natl Cancer Inst. 1992. PMID: 1433368

3

Overexpression and mutation of p53 in endometrial carcinoma.

Kohler MF, Berchuck A, Davidoff AM, Humphrey PA, Dodge RK, Iglehart JD, Soper JT, Clarke-Pearson DL, Bast RC Jr, Marks JR. Kohler MF, et al. Among authors: berchuck a. Cancer Res. 1992 Mar 15;52(6):1622-7. Cancer Res. 1992. PMID: 1540970

4

p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry.

Kerns BJ, Jordan PA, Moore MB, Humphrey PA, Berchuck A, Kohler MF, Bast RC Jr, Iglehart JD, Marks JR. Kerns BJ, et al. Among authors: berchuck a. J Histochem Cytochem. 1992 Jul;40(7):1047-51. doi: 10.1177/40.7.1607637. J Histochem Cytochem. 1992. PMID: 1607637

5

Adjuvant intraperitoneal chromic phosphate therapy for women with apparent early ovarian carcinoma who have not undergone comprehensive surgical staging.

Soper JT, Berchuck A, Clarke-Pearson DL. Soper JT, et al. Among authors: berchuck a. Cancer. 1991 Aug 15;68(4):725-9. doi: 10.1002/1097-0142(19910815)68:4<725::aid-cncr2820680410>3.0.co;2-1. Cancer. 1991. PMID: 1855171

6

Overexpression and mutation of p53 in epithelial ovarian cancer.

Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge RK, Clarke-Pearson DL, Iglehart JD, Bast RC Jr, Berchuck A. Marks JR, et al. Among authors: berchuck a. Cancer Res. 1991 Jun 1;51(11):2979-84. Cancer Res. 1991. PMID: 2032235

7

Transforming growth factor beta 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells.

Elbendary A, Berchuck A, Davis P, Havrilesky L, Bast RC Jr, Iglehart JD, Marks JR. Elbendary A, et al. Among authors: berchuck a. Cell Growth Differ. 1994 Dec;5(12):1301-7. Cell Growth Differ. 1994. PMID: 7696178

8

Loss of heterozygosity on chromosome 17q11-21 in cancers of women who have both breast and ovarian cancer.

Schildkraut JM, Collins NK, Dent GA, Tucker JA, Barrett JC, Berchuck A, Boyd J. Schildkraut JM, et al. Among authors: berchuck a. Am J Obstet Gynecol. 1995 Mar;172(3):908-13. doi: 10.1016/0002-9378(95)90020-9. Am J Obstet Gynecol. 1995. PMID: 7892884

9

Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas.

Liu FS, Kohler MF, Marks JR, Bast RC Jr, Boyd J, Berchuck A. Liu FS, et al. Among authors: berchuck a. Obstet Gynecol. 1994 Jan;83(1):118-24. Obstet Gynecol. 1994. PMID: 8272291

10

The p53 tumor suppressor gene frequently is altered in gynecologic cancers.

Berchuck A, Kohler MF, Marks JR, Wiseman R, Boyd J, Bast RC Jr. Berchuck A, et al. Am J Obstet Gynecol. 1994 Jan;170(1 Pt 1):246-52. doi: 10.1016/s0002-9378(94)70414-7. Am J Obstet Gynecol. 1994. PMID: 8296829 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

633 results

Search Page